IMMU Immunomedics Inc.

18.8
-0.04  -0%
Previous Close 18.84
Open 18.86
Price To Book 13.43
Market Cap 3590047022
Shares 190,959,948
Volume 1,910,176
Short Ratio
Av. Daily Volume 3,514,127

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated.
SACITUZUMAB GOVITECAN
Castration-resistant prostate cancer (CRPC)
Phase 1/2 data February 11, 2019 noted ORR 31% (14/45), with 2 CRs and 12 PRs. Presentation ASCO-GU February 15, 2019.
SACITUZUMAB GOVITECAN
Urothelial cancer
CRL issued January 17, 2019.
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
Phase 2 update provided at ASCO June 2016. Ongoing through 2017.
SACITUZUMAB GOVITECAN
Non-small cell lung cancer (NSCLC)
Phase 2 interim data presented April 2016
Labetuzumab govitecan
Metastatic colorectal cancer (mCRC)
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)
Lupus
Presentation at ASCO June 2018. ORR 31%.
SACTUZUMAB GOVITECAN (IMMU-132)
HR+/HER2- metastatic breast cancer

Latest News

  1. Immunomedics Appoints Barbara G. Duncan to Board of Directors
  2. Immunomedics to Participate in Cowen and Company 39th Annual Health Care Conference
  3. Research Report Identifies Axalta Coating, The Home Depot, Immunomedics, Kosmos Energy, Casa, and Ormat Technologies with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  4. Edited Transcript of IMMU earnings conference call or presentation 25-Feb-19 10:00pm GMT
  5. Lawsuit for Investors in NASDAQ: IMMU shares against Immunomedics, Inc. announced by Shareholders Foundation
  6. The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote
  7. Immunomedics Inc (IMMU) Q4 2018 Earnings Conference Call Transcript
  8. CLASS ACTION UPDATE for IMMU, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  9. Immunomedics Reports Results For Period Ended December 31, 2018, Strengthens Board And Announces Senior Leadership Changes
  10. DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Stockholders of Class Action Against Immunomedics, Inc. (IMMU) & Lead Plaintiff Deadline- February 25, 2019
  11. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DNKEY, IMMU, PRGO and DXC
  12. CLASS ACTION UPDATE for IMMU, DXC and W: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  13. DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Immunomedics, Inc. (IMMU) & Lead Plaintiff Deadline- February 25, 2019
  14. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of IMMU, YRIV, MAXR and SVXY
  15. DEADLINE ALERT - IMMU, ALKS & DXC - Bronstein, Gewirtz & Grossman, LLC
  16. IMMUNOMEDICS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Immunomedics, Inc. - IMMU
  17. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC Technology, Immunomedics, Natural Health, and Maiden Holdings and Encourages Investors to Contact the Firm
  18. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunomedics, Inc. of Class Action Lawsuit and Upcoming Deadline – IMMU
  19. CLASS ACTION UPDATE for SOGO, IMMU, W and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  20. DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Immunomedics, Inc. (IMMU) & Lead Plaintiff Deadline- February 25, 2019